Skip to main content
Signal8

Lantern Pharma Inc. (LTRN) Form 8-K — Nov 18, 2026

$LTRNForm 8-KItems 2.02, 9.01Filed Nov 18, 2026, 7:35 AM ET0001493152-26-052991Original filing

Lantern Pharma reported Q3 2026 results with a GAAP net income of approximately $0.7 million ($0.05/share), driven by a $6.0 million non-cash warrant gain, on a loss from…

Key figures

Eps
0.05
Cash Position
7600000
Gross Proceeds
4000000
Offering Price
1.09
Shares Offered
1469725
Shares Outstanding
14935576
Cash dec 31 2025
$10.1M
Warrant liability
$1.5M
Ga expense q3 2026
$3.8M (up 99% YoY from ~$1.9M)
Rd expense q3 2026
$1.6M (down 36% YoY from ~$2.4M)
Settlement accrual
$2.0M
Non cash warrant gain
$6.0M
Net loss prior year q3
$4.2M ($0.39/share)
Loss from operations q3 2026
$5.4M ($3.4M excluding settlement accrual)
Shares outstanding nov 9 2026
15886576

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    Lantern Pharma Inc. (LTRN) Form 8-K — Nov 18, 2026: AI Analysis | Signal8